203 related articles for article (PubMed ID: 14598186)
1. Prognostic significance of HLA-DR antigen in serous ovarian tumors.
Tamiolakis D; Kotini A; Venizelos J; Jivannakis T; Simopoulos C; Papadopoulos N
Clin Exp Med; 2003 Sep; 3(2):113-8. PubMed ID: 14598186
[TBL] [Abstract][Full Text] [Related]
2. Expression of HLA-DR antigen and characterization of the lymphocytic infiltrate in normal mucosa, tubulo-villous adenoma and invasive carcinoma of the colon.
Tamiolakis D; Venizelos J; Papadopoulos N; Lambropoulou M; Papadopoulos E; Simopoulos C
Chirurgia (Bucur); 2005; 100(5):451-6. PubMed ID: 16372671
[TBL] [Abstract][Full Text] [Related]
3. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
4. Local immune response in serous papillary carcinoma of the endometrium.
Tamiolakis D; Venizelos J; Lambropoulou M; Nikolaidou S; Tsikouras P; Jivannakis T; Papadopoulos N
Histol Histopathol; 2005 Apr; 20(2):403-8. PubMed ID: 15736043
[TBL] [Abstract][Full Text] [Related]
5. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
[TBL] [Abstract][Full Text] [Related]
6. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G
Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133
[TBL] [Abstract][Full Text] [Related]
9. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
11. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
[TBL] [Abstract][Full Text] [Related]
12. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
13. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of HLA-DR antigen in dysplasia, carcinoma in situ and invasive carcinoma of the gallbladder.
Tamiolakis D; Simopoulos C; Kotini A; Venizelos J; Jivannakis T; Skaphida P; Papadopoulos N
East Afr Med J; 2003 Nov; 80(11):554-8. PubMed ID: 15248671
[TBL] [Abstract][Full Text] [Related]
15. Tissue evaluation of immune markers in endometrial and cervical carcinomas.
Lazaris ACh; Chatzigianni EB; Xidias G; Panoskaltsis TA; Thomopoulou GC; Eftychiadis CA; Michalas S; Patsouris ES
J Exp Clin Cancer Res; 2004 Jun; 23(2):269-75. PubMed ID: 15354412
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
17. Activated (HLA-DR+) T-lymphocyte subsets in early epithelial ovarian cancer and malignant ovarian germ cell tumors.
Miyazaki K; Shimada K; Katabuchi H; Arakane F; Arao S; Okamura H
Gynecol Oncol; 1995 Sep; 58(3):362-7. PubMed ID: 7672702
[TBL] [Abstract][Full Text] [Related]
18. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
19. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer.
Eisenthal A; Polyvkin N; Bramante-Schreiber L; Misonznik F; Hassner A; Lifschitz-Mercer B
Hum Pathol; 2001 Aug; 32(8):803-7. PubMed ID: 11521223
[TBL] [Abstract][Full Text] [Related]
20. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.
Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Nillson B; Bergfeldt K; Masucci GV
Gynecol Oncol; 2006 Oct; 103(1):145-50. PubMed ID: 16542716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
